Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + Bendamustine
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Follicular Lymphoma
Conditions
Relapsed/Refractory Follicular Lymphoma
Trial Timeline
Sep 22, 2022 → Oct 1, 2030
NCT ID
NCT05371093About Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + Bendamustine
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + Bendamustine is a phase 3 stage product being developed by Gilead Sciences for Relapsed/Refractory Follicular Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05371093. Target conditions include Relapsed/Refractory Follicular Lymphoma.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Follicular Lymphoma were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05371093 | Phase 3 | Active |
Competing Products
20 competing products in Relapsed/Refractory Follicular Lymphoma